The Latest on Uveal Melanoma Research and Clinical Trials: Updates from the Cure Ocular Melanoma (CURE OM) Science Meeting (2019).
The Latest on Uveal Melanoma Research and Clinical Trials: Updates from the Cure Ocular Melanoma (CURE OM) Science Meeting (2019).
复制标题
DOI：
10.1158/1078-0432.ccr-20-2536
复制
发表时间：
2021-01-01
期刊：
影响因子：
--
通讯作者：
Patel SP
中科院分区：
文献类型：
--
作者：
Chua V;Mattei J;Han A;Johnston L;LiPira K;Selig SM;Carvajal RD;Aplin AE;Patel SP
葡萄膜黑色素瘤（UM）是一种罕见的成人癌症，但其治疗是黑色素瘤领域临床未满足的需求之一。大约50%的患者发生转移性疾病，由于缺乏有效的治疗方案，与生存率低相关。它为显示异常G蛋白偶联受体信号传导、肿瘤休眠、肝选择性转移向性的证据并且与BAP 1肿瘤抑制因子的丧失相关的癌症提供了范例。2019年11月20日，在犹他州举行的黑色素瘤研究协会（SMR）会议上，在黑色素瘤研究基金会（MRF）CURE OM科学会议上，临床医生和研究人员根据UM中的三个主题介绍了他们的研究结果：1）正在进行的临床试验; 2）分子决定因素; 3）可以转化为临床试验的新靶点。这次会议强调了对UM研究领域的高度兴趣以及对晚期疾病有效治疗策略的未满足需求。正在进行的临床试验的结果是有希望的，多项研究表明新的组合策略如何提高应答率。通过生物信息学或高通量筛选确定的新靶点和肿瘤脆弱性也揭示了靶向UM的新机会。UM研究领域追求的未来方向可能会对其他癌症类型产生影响，这些癌症类型具有相似的遗传改变和/或显示相似的生物学特性。
Uveal melanoma (UM) is a rare cancer in adults but its treatment is one of the clinical unmet needs in the melanoma field. Metastatic disease develops in approximately 50% of patients and is associated with poor survival due to the lack of effective treatment options. It provides a paradigm for cancers that show evidence of aberrant G-protein coupled receptor signaling, tumor dormancy, liver-selective metastatic tropism and are associated with the loss of the BAP1 tumor suppressor. At the Melanoma Research Foundation (MRF) CURE OM Science Meeting at the Society for Melanoma Research (SMR) Meeting held in Utah, on November 20, 2019, clinicians and researchers presented findings from their studies according to three themes within UM: 1) ongoing clinical trials; 2) molecular determinants; and 3) novel targets that could be translated into clinical trials. This meeting underscored the high interest in the UM research field and the unmet need for effective treatment strategies for late-stage disease. Findings from ongoing clinical trials are promising and multiple studies show how novel combinatorial strategies increase response rates. Novel targets and tumor vulnerabilities identified bioinformatically or through high-throughput screens also reveal new opportunities to target UM. The future directions pursued by the UM research field will likely have impact of other cancer types, which harbor similar genetic alterations and/or show similar biological properties.